During the first 9 months of fiscal 2008, we've achieved annual revenue growth of 16%, gross margin of 65% and non-GAAP net income that was 9% of revenue," continued Mr. O'Connor. "Based upon our year-to-date performance, we remain on track with our full-year financial guidance."
Pharsight's recent highlights in its software and consulting services
-- Achieved 20% revenue growth in the first nine months of fiscal 2008
compared with the same period of fiscal 2007.
-- Added 21st PKS customer.
-- 38% of PKS installed based purchased additional licenses year-to-date.
-- Achieved third WinNonlin AutoPilot customer.
-- IVIVC Toolkit for WinNonlin surpassed 100th customer milestone.
Strategic Consulting Services (SCS)
-- Continued to diversify revenue base with top five customers
representing 50% of revenue compared with 74% in the same period last
-- Engaged in 9 new projects.
-- Utilized an FDA quantitative disease model for non-small cell lung
cancer to support Pharsight client's oncology drug development program.
-- Continued to make featured presentations at key industry meetings
including the Second Annual Drug Information Association (DIA) Cardiac
Safety Conference, the American Association of Pharmaceutical
Scientists (AAPS) and the Institute for Operations Research and the
Management Sciences (INFORMS).
-- Expanded scientific team with the hiring of an additional senior
Reporting and Analysis Services (RAS)
-- Engaged in a total of 20 different projects for th
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved